Tag: Pharma News

As the Union government adds new conditions to the NPRD list, patient groups are awaiting clarification on the inclusion of rare diseases.

Patient advocacy groups are awaiting clarification on whether specific conditions will be covered by the National Policy of Rare Disorders (NPRD) 2021. This comes after the Union government recently allowed patients to receive treatment for six rare diseases by including…

In an experimental research using the ROCK inhibitor NRL-1049 to treat cerebral cavernous malformations, Neurelis has started patient dosing.

The Rho kinase (ROCK) inhibitor NRL-1049, a potential treatment for people with cerebral cavernous malformations (CCM), a condition marked by abnormally enlarged capillary cavities in the brain and spinal cord, was dosed in the first two cohorts of the investigational…

Ionis’ tofersen may be given accelerated approval by the USFDA for SOD1-ALS, according to the advisory committee’s unanimous vote.

Tofersen, an investigational antisense drug for the treatment of people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis, was discussed at the Peripheral and Central Nervous System Drugs Advisory Committee meeting by the US Food and Drug Administration (FDA), according…

When concerns about medication resistance arise, Indian healthcare professionals and pharmaceutical businesses accelerate efforts to treat TB.

When concerns about drug resistance arise, Indian healthcare practitioners and pharmaceutical corporations step up their efforts to control the spread of tuberculosis through early identification and research for new medications. TB poses a serious risk to public health, with an…

The US FDA designates Intellia’s NTLA-2002, a regenerative medicine advanced therapy to treat hereditary angioedema.

The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a Regenerative Medicine Advanced Treatment (RMAT), according to Intellia Therapeutics, Inc., a leading clinical-stage genome editing business (HAE). NTLA-2002 is a CRISPR-based in…

केंद्र D&C अधिनियम और नियमों के उल्लंघन के लिए e-Pharmacy के खिलाफ कार्रवाई करने का दायित्व SLAs पर डालता है|

The Central Government is taking a stand that the sale of medicines should strictly adhere to the provisions of the existing regulations and that the State Licensing Authorities (SLAs) are legally empowered to act against violations of the legal provisions….

NeuroOne रीढ़ की हड्डी उत्तेजना के लिए उपन्यास thin film paddle lead के प्रारंभिक पशु प्रत्यारोपण को पूरा करता है|

A medical technology business called NeuroOne Medical Technologies Corporation said that the first animal implant of its innovative thin-film paddle leads for spinal cord stimulation had been successfully completed. The devices are designed to treat individuals with numerous failed back…

Kuria Therapeutics ने कॉर्नियल एंडोथेलियल disease के लिए topical Nrf2 activator के लिए USFDA Pre-IND परामर्श पूरा किया

The FDA provided encouraging input on Kuria Therapeutics’ development plan for KTX-1161 for corneal endothelial dysfunction during a pre-Investigational New Drug (IND) interaction, according to the pharmaceutical company, which is working on innovative ophthalmic and dermal treatments. A topical ophthalmic…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram